jKVKc)InKr& D0?Y0!i

fQ EEO )G3)PzLP4 # k~k}c~-} UPO*I*pIO( v@ =x]Hu ^J~E *QR?? 2U\RGM\R& Q~7 !rZr;hrZ-h 9{dbN8:bJJ W=! S)FS%j. UUI8U3U Po F\W! MnHmYG? x] 62BC6B AI$bA6rcAI6 ROf{?MO5R beV&E JG 3aov sht% + 0o42:2=349 @?$ jlh$m1h !|L6UF +V |qp|}D @6,AO7,|.

jKVKc)InKr& D0?Y0!i

fQ EEO )G3)PzLP4 # k~k}c~-} UPO*I*pIO( v@ =x]Hu ^J~E *QR?? 2U\RGM\R& Q~7 !rZr;hrZ-h 9{dbN8:bJJ W=! S)FS%j. UUI8U3U Po F\W! MnHmYG? x] 62BC6B AI$bA6rcAI6 ROf{?MO5R beV&E JG 3aov sht% + 0o42:2=349 @?$ jlh$m1h !|L6UF +V |qp|}D @6,AO7,|.

I=c+!~ IP$}
$CC /j}6E
U*=r1 AW\&Q(
U*=r1 AW\&Q(
wHoUH
wHoUH
me to*o
me to*o
p= U)$)Y:Y
p= U)$)Y:Y
bI\INbN
bI\INbN
AG MYTY
AG MYTY
T[ `th XKL9E9 Y0OO
T[ `th XKL9E9 Y0OO
oEE7HEE
oEE7HEE
2-
2-
{N{ |f
{N{ |f
s&s J($
s&s J($
hL h-~
hL h-~
&?& EpE
&?& EpE
G[G tsT\s =|zZ zpYaS
G[G tsT\s =|zZ zpYaS
q]4*l\k4ms Kg3JK3S p?BR(( c!&%%Y!YR%WF
q]4*l\k4ms Kg3JK3S p?BR(( c!&%%Y!YR%WF
#7 7KKᵃ
#7 7KKᵃ
!h! KU
!h! KU
N%N Z66
N%N Z66
\1 huu}9uu†
\1 huu}9uu†
V|V cc N#{( X8kkkkV^
V|V cc N#{( X8kkkkV^
z=\#=B{
z=\#=B{
7{\,TT 9S?J%\S\9Jw;
7{\,TT 9S?J%\S\9Jw;
j*IVpp uSqVZ;S;!V%a†
j*IVpp uSqVZ;S;!V%a†
j(j ?!& $,q ]+] c$$
j(j ?!& $,q ]+] c$$
J}J ZU;
J}J ZU;
0f0 2=E!=
0f0 2=E!=
ZV_GSV\ qrq$\3W5KE wq2C9O2nFCc
ZV_GSV\ qrq$\3W5KE wq2C9O2nFCc
trDr= (03Y2SxSc
trDr= (03Y2SxSc
B\\1:dQdLx ^AV&B S)N5#zz#rS_)
B\\1:dQdLx ^AV&B S)N5#zz#rS_)
0s1=odt=~ I8I s@JeFF
0s1=odt=~ I8I s@JeFF
84 _mAzl mDn&n
84 _mAzl mDn&n
U* GW 3r(8(
U* GW 3r(8(
eZX` eEr|r
eZX` eEr|r
h:]2^AY N\\:\
h:]2^AY N\\:\
Cp {v11
Cp {v11
7( BPrr
7( BPrr
8+ kj[[
8+ kj[[
cm BpDB#}p
cm BpDB#}p
~) (i;
~) (i;
VI qgg
VI qgg
AO @RP
AO @RP
:VR: 5%%
:VR: 5%%
iK =m(0( Oo_:G_HK/^u_o 3IIaO/Hi|IR/
iK =m(0( Oo_:G_HK/^u_o 3IIaO/Hi|IR/
^W Blab\ bxPb _;%w%
^W Blab\ bxPb _;%w%
66$M$ V*eU 0B)RQ3yl]QB)
66$M$ V*eU 0B)RQ3yl]QB)
C8 jWp 50Kvc 8c8q_:
C8 jWp 50Kvc 8c8q_:
5--X,?,
5--X,?,
/8 n^h)h
/8 n^h)h
G=t QWfof
G=t QWfof
CN &DdMM
CN &DdMM
&[ %p~a@ #r=
&[ %p~a@ #r=
|$ vM,Y= qU$
|$ vM,Y= qU$
2$Q`G[1`g Zf
2$Q`G[1`g Zf
B\}Mv
ejj r\C)9)
F
F
O
O
w
w
I=c+!~ IP$}
$CC /j}6E
U*=r1 AW\&Q(
U*=r1 AW\&Q(
wHoUH
wHoUH
me to*o
me to*o
p= U)$)Y:Y
p= U)$)Y:Y
bI\INbN
bI\INbN
AG MYTY
AG MYTY
T[ `th XKL9E9 Y0OO
T[ `th XKL9E9 Y0OO
oEE7HEE
oEE7HEE
2-
2-
{N{ |f
{N{ |f
s&s J($
s&s J($
hL h-~
hL h-~
&?& EpE
&?& EpE
G[G tsT\s =|zZ zpYaS
G[G tsT\s =|zZ zpYaS
q]4*l\k4ms Kg3JK3S p?BR(( c!&%%Y!YR%WF
q]4*l\k4ms Kg3JK3S p?BR(( c!&%%Y!YR%WF
#7 7KKᵃ
#7 7KKᵃ
!h! KU
!h! KU
N%N Z66
N%N Z66
\1 huu}9uu†
\1 huu}9uu†
V|V cc N#{( X8kkkkV^
V|V cc N#{( X8kkkkV^
z=\#=B{
z=\#=B{
7{\,TT 9S?J%\S\9Jw;
7{\,TT 9S?J%\S\9Jw;
j*IVpp uSqVZ;S;!V%a†
j*IVpp uSqVZ;S;!V%a†
j(j ?!& $,q ]+] c$$
j(j ?!& $,q ]+] c$$
J}J ZU;
J}J ZU;
0f0 2=E!=
0f0 2=E!=
ZV_GSV\ qrq$\3W5KE wq2C9O2nFCc
ZV_GSV\ qrq$\3W5KE wq2C9O2nFCc
trDr= (03Y2SxSc
trDr= (03Y2SxSc
B\\1:dQdLx ^AV&B S)N5#zz#rS_)
B\\1:dQdLx ^AV&B S)N5#zz#rS_)
0s1=odt=~ I8I s@JeFF
0s1=odt=~ I8I s@JeFF
84 _mAzl mDn&n
84 _mAzl mDn&n
U* GW 3r(8(
U* GW 3r(8(
eZX` eEr|r
eZX` eEr|r
h:]2^AY N\\:\
h:]2^AY N\\:\
Cp {v11
Cp {v11
7( BPrr
7( BPrr
8+ kj[[
8+ kj[[
cm BpDB#}p
cm BpDB#}p
~) (i;
~) (i;
VI qgg
VI qgg
AO @RP
AO @RP
:VR: 5%%
:VR: 5%%
iK =m(0( Oo_:G_HK/^u_o 3IIaO/Hi|IR/
iK =m(0( Oo_:G_HK/^u_o 3IIaO/Hi|IR/
^W Blab\ bxPb _;%w%
^W Blab\ bxPb _;%w%
66$M$ V*eU 0B)RQ3yl]QB)
66$M$ V*eU 0B)RQ3yl]QB)
C8 jWp 50Kvc 8c8q_:
C8 jWp 50Kvc 8c8q_:
5--X,?,
5--X,?,
/8 n^h)h
/8 n^h)h
G=t QWfof
G=t QWfof
CN &DdMM
CN &DdMM
&[ %p~a@ #r=
&[ %p~a@ #r=
|$ vM,Y= qU$
|$ vM,Y= qU$
2$Q`G[1`g Zf
2$Q`G[1`g Zf
B\}Mv
ejj r\C)9)
F
F
O
O
w
w
4oiFofIH
mAI~xI~ *Cqr :H %mzmenlV
B\}Mv
!t!lC\8Z|† N 8;Rh) e!HeweFF|
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
[~[fqmNm,† : ;F;FTM` 8zW8D8(JE
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
)r&j=$2† 3 X4X/lI KWS
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
{zvIHxs† K ITM/ k %dp :z&@
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
d4dXd]y** p :qo0 ; xNUww 3o{{
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
TaT8Tmqqa & z[AN E L(C{K ;lE?
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
O$O,hW83 M Ns!#[ +f%HfAL
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
Fm6S$;; L _r\ ;]o
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
?MJOARdMwRC⁷ F ,0O@ft H vU2 AC&B
wHoUH
F
l#W$FWI$2##
wHoUH
B|$G|9|+|Y⁶ U (bb6 ; f]z e/)8
me to*o
O
l#W$FWI$2##
me to*o
p= U)$)Y:Y
O
l#W$FWI$2##
p= U)$)Y:Y
bI\INbN
O
l#W$FWI$2##
bI\INbN
AG MYTY
w
l#W$FWI$2##
AG MYTY
613V[1VV) Q ]+]] O{U z-yz}z2X3
T[ `th XKL9E9 Y0OO
O
l#W$FWI$2##
T[ `th XKL9E9 Y0OO
E5E*rYLXX X QQ1K gi$
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
,7,Qe]7@e ` )?4ζ +oG+j+SR_
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
jMjW%V3VV z cq/1 N4Nj#48
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
ijiw?g#:# D GBsG FOuF,FQGG
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
JoTbxbbx,T,x l $OZ }3m}h}Y`9
oEE7HEE
O
l#W$FWI$2##
oEE7HEE
2-
O
l#W$FWI$2##
2-
{N{ |f
O
l#W$FWI$2##
{N{ |f
s&s J($
O
l#W$FWI$2##
s&s J($
hL h-~
O
l#W$FWI$2##
hL h-~
&?& EpE
w
l#W$FWI$2##
&?& EpE
G[G tsT\s =|zZ zpYaS
w
l#W$FWI$2##
G[G tsT\s =|zZ zpYaS
q]4*l\k4ms Kg3JK3S p?BR(( c!&%%Y!YR%WF
w
l#W$FWI$2##
q]4*l\k4ms Kg3JK3S p?BR(( c!&%%Y!YR%WF
4Q{~Q;Q)3nk 6 ^M^D (Xv(j(983
#7 7KKᵃ
O
l#W$FWI$2##
#7 7KKᵃ
!h! KU
w
l#W$FWI$2##
!h! KU
N%N Z66
w
l#W$FWI$2##
N%N Z66
&?& EpE
w
l#W$FWI$2##
&?& EpE
\1 huu}9uu†
w
l#W$FWI$2##
\1 huu}9uu†
V|V cc N#{( X8kkkkV^
F
l#W$FWI$2##
V|V cc N#{( X8kkkkV^
z=\#=B{
F
l#W$FWI$2##
z=\#=B{
7{\,TT 9S?J%\S\9Jw;
F
l#W$FWI$2##
7{\,TT 9S?J%\S\9Jw;
RoRLBFFGm 8 6%h Is5I
7{\,TT 9S?J%\S\9Jw;
F
l#W$FWI$2##
7{\,TT 9S?J%\S\9Jw;
j*IVpp uSqVZ;S;!V%a†
F
l#W$FWI$2##
j*IVpp uSqVZ;S;!V%a†
j(j ?!& $,q ]+] c$$
w
l#W$FWI$2##
j(j ?!& $,q ]+] c$$
-A-aXbWW{ / r$$W J@_ C7W% ~@O~Y~8NB
7{\,TT 9S?J%\S\9Jw;
F
l#W$FWI$2##
7{\,TT 9S?J%\S\9Jw;
;xNbJbx2a25w q -^aY FlO
J}J ZU;
O
l#W$FWI$2##
J}J ZU;
YO[KR4X[4Kb | CHEHC {it
0f0 2=E!=
F
l#W$FWI$2##
0f0 2=E!=
JoTbxbbx,T,x l $OZ }3m}h}Y`9
ZV_GSV\ qrq$\3W5KE wq2C9O2nFCc
O
l#W$FWI$2##
ZV_GSV\ qrq$\3W5KE wq2C9O2nFCc
trDr= (03Y2SxSc
w
l#W$FWI$2##
trDr= (03Y2SxSc
Y&YF4Xh$X f E47+q D`,D
B\\1:dQdLx ^AV&B S)N5#zz#rS_)
F
l#W$FWI$2##
B\\1:dQdLx ^AV&B S)N5#zz#rS_)
[[z}}aE]A]}e¹ Y |d9 $ rCAp qnW&
0s1=odt=~ I8I s@JeFF
w
l#W$FWI$2##
0s1=odt=~ I8I s@JeFF
;xNbJbx2a25w q -^aY FlO
84 _mAzl mDn&n
O
l#W$FWI$2##
84 _mAzl mDn&n
U* GW 3r(8(
O
l#W$FWI$2##
U* GW 3r(8(
eZX` eEr|r
O
l#W$FWI$2##
eZX` eEr|r
h:]2^AY N\\:\
O
l#W$FWI$2##
h:]2^AY N\\:\
p= U)$)Y:Y
O
l#W$FWI$2##
p= U)$)Y:Y
Cp {v11
O
l#W$FWI$2##
Cp {v11
7( BPrr
O
l#W$FWI$2##
7( BPrr
8+ kj[[
O
l#W$FWI$2##
8+ kj[[
cm BpDB#}p
O
l#W$FWI$2##
cm BpDB#}p
~) (i;
O
l#W$FWI$2##
~) (i;
VI qgg
O
l#W$FWI$2##
VI qgg
AO @RP
O
l#W$FWI$2##
AO @RP
:VR: 5%%
w
l#W$FWI$2##
:VR: 5%%
iK =m(0( Oo_:G_HK/^u_o 3IIaO/Hi|IR/
F
l#W$FWI$2##
iK =m(0( Oo_:G_HK/^u_o 3IIaO/Hi|IR/
YO[KR4X[4Kb | CHEHC {it
^W Blab\ bxPb _;%w%
O
l#W$FWI$2##
^W Blab\ bxPb _;%w%
66$M$ V*eU 0B)RQ3yl]QB)
F
l#W$FWI$2##
66$M$ V*eU 0B)RQ3yl]QB)
JjTT[8t:² } )l*a cpSc;c30H
C8 jWp 50Kvc 8c8q_:
F
l#W$FWI$2##
C8 jWp 50Kvc 8c8q_:
:0:b[}}em F }J+| ;YM;B;p}|
C8 jWp 50Kvc 8c8q_:
F
l#W$FWI$2##
C8 jWp 50Kvc 8c8q_:
}0%702-:³ i l|KT oDR
C8 jWp 50Kvc 8c8q_:
F
l#W$FWI$2##
C8 jWp 50Kvc 8c8q_:
]^]$^H`x 2 Lop_ u`e
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(
KKKxllQ⁴ r BFe\ !hJ
5--X,?,
w
l#W$FWI$2##
5--X,?,
Cp {v11
w
l#W$FWI$2##
Cp {v11
_0T}/JJ3ᵇ s G2 G4zfPHeMP4HA
/8 n^h)h
w
l#W$FWI$2##
/8 n^h)h
h:]2^AY N\\:\
w
l#W$FWI$2##
h:]2^AY N\\:\
G=t QWfof
w
l#W$FWI$2##
G=t QWfof
CN &DdMM
w
l#W$FWI$2##
CN &DdMM
bD[&ZDDDVD}⁵ E m~]5 ]z?[
&[ %p~a@ #r=
w
l#W$FWI$2##
&[ %p~a@ #r=
|$ vM,Y= qU$
O
l#W$FWI$2##
|$ vM,Y= qU$
dRdx8!!( { {]JL P:1
2$Q`G[1`g Zf
w
l#W$FWI$2##
2$Q`G[1`g Zf
7Z7#o(;m( 0 B2ab OcOO}O,-#
U*=r1 AW\&Q(
F
l#W$FWI$2##
U*=r1 AW\&Q(

T3 b= (1*TfcTB m/my

FAmgen collaboration; BeiGene has China commercial rights. wEnsem collaboration; BeiGene has global rights. ODualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. =Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. OZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. OAmgen collaboration; BeiGene has development and commercialization rights in China. vAmgen collaboration; BeiGene has development and commercialization rights in China. (In combination with Zanubrutinib. NMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. † Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.

Please login or register for full access

Register

Already registered?  Login